DOCSLIB.ORG

2020 ESC Guidelin Es for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2020 ESC Guidelin Es for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation 1 2020 ESC Guidelin es for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-seg- ment elevation of the European Society of Cardiology (ESC) ESC Guidelines ESC Guidelines Authors/Task Force Members: Jean-Philippe Collet* (Chairperson) [AQ7](France), Holger Thiele* (Chairperson) (Germany), Emanuele Barbato (Italy), Olivier Barthélémy (France), Johann Bauersachs (Germany), Deepak L. Bhatt (USA), Paul Dendale (Belgium), Maria Dorobantu (Romania), Thor Edvardsen (Norway), Thierry Folliguet (France), Chris P. Gale (UK), Martine Gilard (France), Alexander Jobs (Germany), Peter Jüni (Canada), Ekaterini Lambrinou (Cyprus), Basil S. Lewis (Israel), Julinda Mehilli (Germany), Emanuele Meliga (Italy), Béla Merkely (Hungary), Christian Mueller (Switzerland), Marco Roffi (Switzerland), Frans H. Rutten (Netherlands), Dirk Sibbing (Germany), George C.M. Siontis (Switzerland) Document Reviewers: Adnan Kastrati (CPG Review Coordinator) (Germany), Mamas A. Mamas (CPG Review Coordinator) (UK), Victor Aboyans (France), Dominick J. Angiolillo (USA), Hector Bueno (Spain), Raffaele Bugiardini (Italy), Robert A. Byrne (Ireland), Silvia Castelletti (Italy), Alaide Chieffo (Italy), Veronique Cornelissen (Belgium), Filippo Crea (Italy), Victoria Delgado (Netherlands), Heinz Drexel (Austria), Marek Gierlotka (Poland), Sigrun Halvorsen (Norway), Kristina Hermann Haugaa (Norway), Ewa A. Jankowska (Poland), Hugo A. Katus (Germany), Tim Kinnaird (UK), Jolanda Kluin (Netherlands), Vijay Kunadian (UK), Ulf Landmesser (Germany), Christophe Leclercq (France), Maddalena Lettino (Italy), Leena Meinila (Finland), Darren My- lotte (Ireland), Gjin Ndrepepa (Germany), Elmir Omerovic (Sweden), Roberto F. E. Pedretti (Ita- ly), Steffen E. Petersen (UK), Anna Sonia Petronio (Italy), Gianluca Pontone (Italy), Bogdan A. Popescu (Romania), Tatjana Potpara (Serbia), Kausik K. Ray (UK), Flavio Luciano Ribichini (Ita- ly), Dimitrios J. Richter (Greece), Evgeny Shlyakhto (Russian Federation), Iain A. Simpson (UK), Miguel Sousa-Uva (Portugal), Robert F. Storey (UK), Rhian M. Touyz (UK), Marco Valgimigli (Switzerland), Pascal Vranckx (Belgium), Robert W. Yeh (USA) The disclosure forms of all ex- perts involved in the development of these guidelines are available on the ESC website www.escardio.org/guidelines For the Supplementary Data which include background informa- tion and detailed discussion of the data that have provided the basis for the Guidelines see European Heart Journal online. * Corresponding authors: Jean-Philippe Collet, Sorbonne Université, ACTION Study Group, INSERM UMRS 1166, Institut de Cardio- logie, Hôpital Pitié-Salpêtrière (Assistance Publique- Hôpitaux de Paris) (AP-HP), 83, boulevard de l'Hôpital, 75013 Paris, France. Tel + 33 01 42 16 29 62, E-mail: [email protected]. Holger Thiele, Department of Internal Medicine/Cardiology, Heart Center Leipzig at University of Leipzig, Strümpellstr. 39, 04289 Leipzig, Germany. Tel: +49 341 865 1428, Fax: +49 341 865 1461, E- mail: [email protected]. ESC Committee for Practice Guidelines (CPG) and National Cardiac Societies document reviewers: listed in the Appendix. ESC entities having participated in the development of this document: Associations: Association for Acute CardioVascular Care (ACVC), Association of Cardiovascular Nursing & Allied Professions (AC- NAP), European Association of Cardiovascular Imaging (EACVI), European Association of Preventive Cardiology (EAPC), European © Copyrights 2020 Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), Heart Failure As- sociation (HFA). Councils: Council for Cardiology Practice. Working Groups: Cardiovascular Pharmacotherapy, Cardiovascular Surgery, Coronary Pathophysiology and Microcirculation, Thrombosis. The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford University Press, the publish- er of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permis- [email protected]). Disclaimer. The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge, and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropri- ate and/or necessary, the patient’s caregiver. Nor do the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authori- ties, in order to manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription. Keywords: Guidelines acute cardiac care acute coronary syndrome angioplasty anticoagulation antiplatelet apixa- ban aspirin atherothrombosis betablockers bleedings bivalirudin bypass surgery cangrelor chest pain unit clopidog- rel dabigatran diabetes dual antithrombotic therapy early invasive strategy edoxaban enoxaparin European Society of Cardiology fondaparinux glycoprotein IIb/IIIa inhibitors heparin high-sensitivity troponin minoca myocardial ischae- mia myocardial infarction nitrates non-ST-elevation myocardial infarction platelet inhibition prasugrel recommenda- tions revascularization rhythm monitoring rivaroxaban stent ticagrelor triple therapy unstable angina Table of contents •1. Abbreviations and acronyms 5 •2. 1 Preamble 7 •3. 2 Introduction 8 •4. 2.1 Definitions 8 •5. 2.1.1 Universal definition of myocardial infarction 8 •6. 2.1.1.1 Type 1 myocardial infarction 8 •7. 2.1.1.2 Type 2 myocardial infarction 9 •8. 2.1.1.3 Types 3–5 myocardial infarction 9 •9. 2.1.2 Unstable angina in the era of high-sensitivity cardiac troponin assays 9 •10. 2.2 Epidemiology 9 •11. 2.3 What is new? 9 •12. 2.4 Number and breakdown of classes of recommendations (Supplementary Data) 10 •13. 3 Diagnosis 10 © Copyrights 2020 •14. 3.1 Clinical presentation (Supplementary Data) 10 •15. 3.2 Physical examination (Supplementary Data) 10 •16. 3.3 Diagnostic tools 10 •17. 3.3.1 Electrocardiogram 10 •18. 3.3.2 Biomarkers: high-sensitivity cardiac troponin 11 •19. 3.3.2.1 Central laboratory vs. point-of-care 12 •20. 3.3.2.2 Other biomarkers 13 •21. 3.3.3 Rapid ‘rule-in’ and ‘rule-out’ algorithms 13 •22. 3.3.4 Observe 15 •23. 3.3.4.1 Caveats of using rapid algorithms 15 •24. 3.3.4.2 Confounders of cardiac troponin concentration 15 •25. 3.3.4.3 Practical guidance on how to implement the European Society of Cardiology 0 h/1 h algorithm 16 •26. 3.3.4.4 Avoiding misunderstandings: time to decision = time of blood drawrn-around time 16 •27. 3.3.5 Non-invasive imaging 17 •28. 3.3.5.1 Functional evaluation 17 •29. 3.3.5.2 Anatomical evaluation 17 •30. 3.4 Differential diagnosis 17 •31. 4 Risk assessment and outcomes 19 •32. 4.1 Electrocardiogram indicators (Supplementary Data) 19 •33. 4.2 Biomarkers 19 •34. 4.3 Clinical scores for risk assessment (Supplementary Data) 19 •35. 4.4 Bleeding risk assessment 20 •36. 4.5 Integrating ischaemic and bleeding risks 21 •37. 5 Pharmacological treatments 21 •38. 5.1 Antithrombotic treatment 21 •39. 5.1.1 Antiplatelet drugs and pre-treatment 23 •40. 5.1.1.1 Antiplatelet drugs and dual antiplatelet therapy 23 •41. 5.1.1.2 Pre-treatment 24 •42. 5.1.2 Peri-interventional anticoagulant treatment 26 •43. 5.1.3 Peri-interventional antiplatelet treatment 27 •44. 5.1.4 Post-interventional and maintenance treatment 27 •45. 5.2 Pharmacological treatment of ischaemia (Supplementary Data) 30 •46. 5.2.1 Supportive pharmacological treatment (Supplementary Data) 30 •47. 5.2.2 Nitrates and beta-blockers (Supplementary Data) 30 •48. 5.3 Managing oral antiplatelet agents in patients requiring long-termoral anticoagulants 30 •49. 5.3.1 Patients with atrial fibrillation without mechanical prosthetic heart valves ormoderate-to- severe mitral stenosis undergoing percutaneous coronary intervention or managedmedically (Sup‐ plementary Data) 30 © Copyrights 2020 •50. 5.3.2 Patients requiring vitamin K antagonists or undergoing coronary artery bypass surgery 32 •51. 5.4 Management of acute bleeding events (Supplementary Data) 34 •52. 5.4.1
Load more

Recommended publications
  • Rolling Stone Magazine's Top 500 Songs
    Rolling Stone Magazine's Top 500 Songs No. Interpret Title Year of release 1. Bob Dylan Like a Rolling Stone 1961 2. The Rolling Stones Satisfaction 1965 3. John Lennon Imagine 1971 4. Marvin Gaye What’s Going on 1971 5. Aretha Franklin Respect 1967 6. The Beach Boys Good Vibrations 1966 7. Chuck Berry Johnny B. Goode 1958 8. The Beatles Hey Jude 1968 9. Nirvana Smells Like Teen Spirit 1991 10. Ray Charles What'd I Say (part 1&2) 1959 11. The Who My Generation 1965 12. Sam Cooke A Change is Gonna Come 1964 13. The Beatles Yesterday 1965 14. Bob Dylan Blowin' in the Wind 1963 15. The Clash London Calling 1980 16. The Beatles I Want zo Hold Your Hand 1963 17. Jimmy Hendrix Purple Haze 1967 18. Chuck Berry Maybellene 1955 19. Elvis Presley Hound Dog 1956 20. The Beatles Let It Be 1970 21. Bruce Springsteen Born to Run 1975 22. The Ronettes Be My Baby 1963 23. The Beatles In my Life 1965 24. The Impressions People Get Ready 1965 25. The Beach Boys God Only Knows 1966 26. The Beatles A day in a life 1967 27. Derek and the Dominos Layla 1970 28. Otis Redding Sitting on the Dock of the Bay 1968 29. The Beatles Help 1965 30. Johnny Cash I Walk the Line 1956 31. Led Zeppelin Stairway to Heaven 1971 32. The Rolling Stones Sympathy for the Devil 1968 33. Tina Turner River Deep - Mountain High 1966 34. The Righteous Brothers You've Lost that Lovin' Feelin' 1964 35.
    [Show full text]
  • (Pdf) Download
    Artist Song 2 Unlimited Maximum Overdrive 2 Unlimited Twilight Zone 2Pac All Eyez On Me 3 Doors Down When I'm Gone 3 Doors Down Away From The Sun 3 Doors Down Let Me Go 3 Doors Down Behind Those Eyes 3 Doors Down Here By Me 3 Doors Down Live For Today 3 Doors Down Citizen Soldier 3 Doors Down Train 3 Doors Down Let Me Be Myself 3 Doors Down Here Without You 3 Doors Down Be Like That 3 Doors Down The Road I'm On 3 Doors Down It's Not My Time (I Won't Go) 3 Doors Down Featuring Bob Seger Landing In London 38 Special If I'd Been The One 4him The Basics Of Life 98 Degrees Because Of You 98 Degrees This Gift 98 Degrees I Do (Cherish You) 98 Degrees Feat. Stevie Wonder True To Your Heart A Flock Of Seagulls The More You Live The More You Love A Flock Of Seagulls Wishing (If I Had A Photograph Of You) A Flock Of Seagulls I Ran (So Far Away) A Great Big World Say Something A Great Big World ft Chritina Aguilara Say Something A Great Big World ftg. Christina Aguilera Say Something A Taste Of Honey Boogie Oogie Oogie A.R. Rahman And The Pussycat Dolls Jai Ho Aaliyah Age Ain't Nothing But A Number Aaliyah I Can Be Aaliyah I Refuse Aaliyah Never No More Aaliyah Read Between The Lines Aaliyah What If Aaron Carter Oh Aaron Aaron Carter Aaron's Party (Come And Get It) Aaron Carter How I Beat Shaq Aaron Lines Love Changes Everything Aaron Neville Don't Take Away My Heaven Aaron Neville Everybody Plays The Fool Aaron Tippin Her Aaron Watson Outta Style ABC All Of My Heart ABC Poison Arrow Ad Libs The Boy From New York City Afroman Because I Got High Air
    [Show full text]
  • Plant Responses to Abiotic Stresses and Rhizobacterial Biostimulants: Metabolomics and Epigenetics Perspectives
    H OH metabolites OH Review Plant Responses to Abiotic Stresses and Rhizobacterial Biostimulants: Metabolomics and Epigenetics Perspectives Motseoa M. Lephatsi 1 , Vanessa Meyer 2 , Lizelle A. Piater 1 , Ian A. Dubery 1 and Fidele Tugizimana 1,3,* 1 Department of Biochemistry, University of Johannesburg, Auckland Park, Johannesburg 2006, South Africa; [email protected] (M.M.L.); [email protected] (L.A.P.); [email protected] (I.A.D.) 2 School of Molecular and Cell Biology, University of the Witwatersrand, Private Bag 3, WITS, Johannesburg 2050, South Africa; [email protected] 3 International Research and Development Division, Omnia Group, Ltd., Johannesburg 2021, South Africa * Correspondence: [email protected]; Tel.: +27-011-559-7784 Abstract: In response to abiotic stresses, plants mount comprehensive stress-specific responses which mediate signal transduction cascades, transcription of relevant responsive genes and the accumulation of numerous different stress-specific transcripts and metabolites, as well as coordinated stress-specific biochemical and physiological readjustments. These natural mechanisms employed by plants are however not always sufficient to ensure plant survival under abiotic stress conditions. Biostimulants such as plant growth-promoting rhizobacteria (PGPR) formulation are emerging as novel strategies for improving crop quality, yield and resilience against adverse environmental conditions. However, to successfully formulate these microbial-based biostimulants and design efficient application programs, the understanding of molecular and physiological mechanisms that govern biostimulant-plant interactions is imperatively required. Systems biology approaches, such as Citation: Lephatsi, M.M.; Meyer, V.; metabolomics, can unravel insights on the complex network of plant-PGPR interactions allowing for Piater, L.A.; Dubery, I.A.; Tugizimana, the identification of molecular targets responsible for improved growth and crop quality.
    [Show full text]
  • Men Final Entries
    Final Entries - Athletes List by event European Athletics Indoor Championships 2021, Torun/POL Tot. Number of countries Tot. Number of athletes Tot. Number of Men Tot. Number of Women 47 733 405 328 FINAL ENTRIES - Men 60m Senior Men Num. of countries: 33 Num. of athletes: 71 Member Federation Surname First Name DoB PB SB ARM Donigian Alexander 20/10/1993 6.64i 6.79i ART Keletela Dorian Celeste 06/02/1999 6.79i 6.85i AUT Fuchs Markus 14/11/1995 6.62i 6.69i BEL Kuba Di-Vita Gaylord 17/11/1995 6.73i 6.75i BEL Vleminckx Kobe 31/05/1998 6.65i 6.65i BLR Bliznets Dzianis 12/03/1995 6.75i 6.75i BLR Bohdan Maksim 19/03/1997 6.77i 6.77i BLR Zabalotny Yury 24/02/1997 6.72i 6.72i BUL Dimitrov Denis 10/02/1994 6.65i 6.73i BUL Jivkov Vesselin 26/01/2001 6.76i 6.80i CZE Hampl Štěpán 10/11/1999 6.70i 6.70i CZE Stromšík Zdeněk 25/11/1994 6.60i 6.68i CZE Veleba Jan 06/12/1986 6.65i 6.65i DEN Hansen Simon 30/06/1998 6.75i 6.75i DEN Kjær Emil Mader 20/12/1999 6.77i 6.77i DEN Musah Kojo 15/04/1996 6.61i 6.61i ESP López Sergio 05/07/1999 6.67i 6.74i ESP Rodríguez Daniel 26/01/1995 6.67i 6.67i ESP Sanchez Ricardo 10/08/1999 6.75i 6.75i EST Nazarov Karl Erik 17/03/1999 6.63i 6.63i FIN Illukka Riku 21/09/1999 6.73i 6.73i FIN Purola Samuel 19/05/2000 6.67i 6.67i FIN Samuelsson Samuli 23/06/1995 6.66i 6.66i FRA Fall Mouhamadou 25/02/1992 6.62i 6.62i FRA Golitin Amaury 28/01/1997 6.62i 6.62i GBR Aikines-Aryeetey Harry 29/08/1988 6.55i 6.67i GBR Bromby Oliver 30/03/1998 6.63i 6.65i GBR Robertson Andrew 17/12/1990 6.54i 6.61i GER Corucle Philipp 18/07/1997 6.62i
    [Show full text]
  • Distinct Types of Short Open Reading Frames Are Translated in Plant Cells
    Downloaded from genome.cshlp.org on September 30, 2021 - Published by Cold Spring Harbor Laboratory Press 1 Distinct types of short open reading frames are translated in 2 plant cells 3 4 Igor Fesenko1,*, Ilya Kirov2, Andrey Kniazev1, Regina Khazigaleeva1, Vassili Lazarev3,4, Daria 5 Kharlampieva3, Ekaterina Grafskaia3,4, Viktor Zgoda5, Ivan Butenko3, Georgy Arapidi1,3, Anna 6 Mamaeva1, Vadim Ivanov1, Vadim Govorun3. 7 1Laboratory of functional genomics and plant proteomics, Shemyakin and Ovchinnikov Institute of 8 Bioorganic Chemistry, Moscow, Russian Federation; 2Laboratory of marker-assisted and genomic 9 selection of plants, All-Russian Research Institute of Agricultural Biotechnology, Moscow, Russian 10 Federation; 3 Research Institute for Physico-Chemical Medicine, Moscow, Russian Federation; 4Moscow 11 Institute of Physics and Technology, Dolgoprudny, Moscow region, Russia; 5Laboratory of System 12 Biology, Institute of Biomedical Chemistry, Moscow, Russian Federation. 13 14 Corresponding author(s). 15 * Igor Fesenko, e-mail: [email protected] 16 17 Running title: Translation of sORFs in moss 18 19 Keywords: short open reading frames, plant peptides, LC-MS/MS, evolution, alternative splicing, 20 lncRNA 21 22 ABSTRACT 23 Genomes contain millions of short (<100 codons) open reading frames (sORFs), which are usually 24 dismissed during gene annotation. Nevertheless, peptides encoded by such sORFs can play important 25 biological roles, and their impact on cellular processes has long been underestimated. Here, we 1 Downloaded from genome.cshlp.org on September 30, 2021 - Published by Cold Spring Harbor Laboratory Press 26 analyzed approximately 70,000 transcribed sORFs in the model plant Physcomitrella patens (moss). 27 Several distinct classes of sORFs that differ in terms of their position on transcripts and the level of 28 evolutionary conservation are present in the moss genome.
    [Show full text]
  • ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation
    European Heart Journal (2020) 00,1À126 ESC GUIDELINES doi:10.1093/eurheartj/ehaa612 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in Downloaded from https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaa612/5899003 by guest on 31 August 2020 collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC Authors/Task Force Members: Gerhard Hindricks* (Chairperson) (Germany), Tatjana Potpara* (Chairperson) (Serbia), Nikolaos Dagres (Germany), Elena Arbelo (Spain), Jeroen J. Bax (Netherlands), Carina Blomstro¨m-Lundqvist (Sweden), Giuseppe Boriani (Italy), Manuel Castella1 (Spain), Gheorghe-Andrei Dan (Romania), Polychronis E. Dilaveris (Greece), Laurent Fauchier (France), Gerasimos Filippatos (Greece), Jonathan M. Kalman (Australia), Mark La Meir1 * Corresponding authors: The two chairpersons contributed equally to the document. Gerhard Hindricks, University Clinic of Cardiology, Heart Center Leipzig, Department of Cardiology and Electrophysiology, Leipzig Heart Institute, Stru¨mpellstr. 39, 04289 Leipzig, Germany. Tel: þ49 34 1865 1410, Fax: þ49 34 1865 1460, Email: [email protected] Tatjana Potpara, School of Medicine, Belgrade University, dr Subotica 8, 11000 Belgrade, Serbia, and Cardiology Clinic, Clinical Centre of Serbia,
    [Show full text]
  • The SH-SY5Y Cell Line in Parkinson's Disease Research
    Xicoy et al. Molecular Neurodegeneration (2017) 12:10 DOI 10.1186/s13024-017-0149-0 REVIEW Open Access The SH-SY5Y cell line in Parkinson’s disease research: a systematic review Helena Xicoy1,2, Bé Wieringa1 and Gerard J.M. Martens2* Abstract Parkinson’s disease (PD) is a devastating and highly prevalent neurodegenerative disease for which only symptomatic treatment is available. In order to develop a truly effective disease-modifying therapy, improvement of our current understanding of the molecular and cellular mechanisms underlying PD pathogenesis and progression is crucial. For this purpose, standardization of research protocols and disease models is necessary. As human dopaminergic neurons, the cells mainly affected in PD, are difficult to obtain and maintain as primary cells, current PD research is mostly performed with permanently established neuronal cell models, in particular the neuroblastoma SH-SY5Y lineage. This cell line is frequently chosen because of its human origin, catecholaminergic (though not strictly dopaminergic) neuronal properties, and ease of maintenance. However, there is no consensus on many fundamental aspects that are associated with its use, such as the effects of culture media composition and of variations in differentiation protocols. Here we present the outcome of a systematic review of scientific articles that have used SH-SY5Y cells to explore PD. We describe the cell source, culture conditions, differentiation protocols, methods/approaches used to mimic PD and the preclinical validation of the SH-SY5Y findings by employing alternative cellular and animal models. Thus, this overview may help to standardize the use of the SH-SY5Y cell line in PD research and serve as a future user’sguide.
    [Show full text]
  • Deutsche Nationalbibliografie 2017 a 08
    Deutsche Nationalbibliografie Reihe A Monografien und Periodika des Verlagsbuchhandels Wöchentliches Verzeichnis Jahrgang: 2017 A 08 Stand: 22. Februar 2017 Deutsche Nationalbibliothek (Leipzig, Frankfurt am Main) 2017 ISSN 1869-3946 urn:nbn:de:101-201612063930 2 Hinweise Die Deutsche Nationalbibliografie erfasst eingesandte Pflichtexemplare in Deutschland veröffentlichter Medienwerke, aber auch im Ausland veröffentlichte deutschsprachige Medienwerke, Übersetzungen deutschsprachiger Medienwerke in andere Sprachen und fremdsprachige Medienwerke über Deutschland im Original. Grundlage für die Anzeige ist das Gesetz über die Deutsche Nationalbibliothek (DNBG) vom 22. Juni 2006 (BGBl. I, S. 1338). Monografien und Periodika (Zeitschriften, zeitschriftenartige Reihen und Loseblattausgaben) werden in ihren unterschiedlichen Erscheinungsformen (z.B. Papierausgabe, Mikroform, Diaserie, AV-Medium, elektronische Offline-Publikationen, Arbeitstransparentsammlung oder Tonträger) angezeigt. Alle verzeichneten Titel enthalten einen Link zur Anzeige im Portalkatalog der Deutschen Nationalbibliothek und alle vorhandenen URLs z.B. von Inhaltsverzeichnissen sind als Link hinterlegt. In Reihe A werden Medienwerke, die im Verlagsbuch- chende Menüfunktion möglich. Die Bände eines mehrbän- handel erscheinen, angezeigt. Auch außerhalb des Ver- digen Werkes werden, sofern sie eine eigene Sachgrup- lagsbuchhandels erschienene Medienwerke werden an- pe haben, innerhalb der eigenen Sachgruppe aufgeführt, gezeigt, wenn sie von gewerbsmäßigen Verlagen vertrie- ansonsten
    [Show full text]
  • Human Genetics and Clinical Aspects of Neurodevelopmental Disorders
    bioRxiv preprint doi: https://doi.org/10.1101/000687; this version posted October 6, 2014. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Human genetics and clinical aspects of neurodevelopmental disorders Gholson J. Lyon1,2,3,*, Jason O’Rawe1,3 1Stanley Institute for Cognitive Genomics, One Bungtown Road, Cold Spring Harbor Laboratory, NY, USA, 11724 2Institute for Genomic Medicine, Utah Foundation for Biomedical Research, E 3300 S, Salt Lake City, Salt Lake City, UT, USA, 84106 3Stony Brook University, 100 Nicolls Rd, Stony Brook, NY, USA, 11794 * Corresponding author: Gholson J. Lyon Email: [email protected] Other author emails: Jason O'Rawe: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/000687; this version posted October 6, 2014. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Introduction “our incomplete studies do not permit actual classification; but it is better to leave things by themselves rather than to force them into classes which have their foundation only on paper” – Edouard Seguin (Seguin, 1866) “The fundamental mistake which vitiates all work based upon Mendel’s method is the neglect of ancestry, and the attempt to regard the whole effect upon off- spring, produced by a particular parent, as due to the existence in the parent of particular structural characters; while the contradictory results obtained by those who have observed the offspring of parents apparently identical in cer- tain characters show clearly enough that not only the parents themselves, but their race, that is their ancestry, must be taken into account before the result of pairing them can be predicted” – Walter Frank Raphael Weldon (Weldon, 1902).
    [Show full text]
  • The Critical Role of Histone Methylation in Tumour Progression and As Anti-Cancer Targets in Neuroblastoma
    The critical role of histone methylation in tumour progression and as anti-cancer targets in neuroblastoma Matthew Wong A thesis in fulfilment of the requirements for the degree of Doctor of Philosophy Supervisor: Dr Tao Liu Co-supervisor: A. Prof Patsie Polly School of Women’s and Children’s Health Faculty of Medicine February 2016 PLEASE TYPE THE UNIVERSITY OF NEW SOUTH WALES Thesis/Dissertation Sheet Surname or Family name: First name: Matthew Other name/s: Kwok Kei Wong Abbreviation for degree as given in the University calendar: PhD School: School of Women’s and Children’s Heath Faculty: Faculty of Medicine Title: The critical role of histone methylation in tumour progression and as anti-cancer targets in neuroblastoma N-Myc induces neuroblastoma by regulating the expression of target oncogenes. Histone H3 lysine 79 (H3K79) methylation at Myc-responsive elements of target gene promoters is a strict prerequisites for Myc-induced transcriptional activation. DOT1L is the only known histone methyltransferase that catalyses mono-methylation (me), di- methylation (me2) and tri-methylation (me3) at the histone H3K79 position, which have been linked to gene transcriptional activation. JMJD6 is a bi-functional arginine demethylase and lysyl-hydroxylase. The JMJD6 gene is located on the chromosome 17q25 position. 17q21-gter gain has been identified as the most frequent chromosome alternation in neuroblastoma and an indicator of poor patient prognostic. Here, I investigated the roles of DOT1L and JMJD6 in N-Myc over-expressing neuroblastoma. I found that N-Myc up-regulated DOT1L mRNA and protein expression, by binding to an E-box at the DOT1L gene promoter.
    [Show full text]
  • Phi Theta Kappa's Satellite Seminar
    October 2006Online at: http://www.bergen.edu/pages/880.asp Vol. XII Issue 2 Phi Theta Kappa’s Satellite Seminar Series Presents: Gender and Power in Relationships BY: MARIYA GONOR STAFF WRITER For many years, Phi Theta Kappa’s satellite seminars have been a great way to educate the students of Bergen about the important issues of our present time. This year will be no different. Our Alpha Epsilon Phi chapter of Phi Theta Kappa will continue to promote scholarship among our peers. Also, this year students who attend the seminar not only have a chance to learn a lot from the speaker, but they can also express their opinion on the subject mat- PTK President, Mariya Gonor ter. Each seminar is being followed dynamics of power. By exploring The first seminar was by a discussion, which is important power in all the different ways it Q.held on September 26th. because we, as students, have voic- appears, we will be trying to Did you find it successful and es that have to be heard. enhance an intelligent climate what was the part that you liked The first seminar was held on the among all the students. In addition the most? 26th of September in room C-102. Presenter: Dr. Pepper Schwartz to the different topics presented, I definitely consider the The topic of that seminar con- are very important for students of So I heard that this year's this year’s seminars will be held in first seminar to be a suc- cerned power in relationships. Dr. A.
    [Show full text]
  • A Foundation for the Future
    A FOUNDATION FOR THE FUTURE INVESTORS REPORT 2012–13 NORTHWESTERN UNIVERSITY Dear alumni and friends, As much as this is an Investors Report, it is also living proof that a passion for collaboration continues to define the Kellogg community. Your collective support has powered the forward movement of our ambitious strategic plan, fueled development of our cutting-edge curriculum, enabled our global thought leadership, and helped us attract the highest caliber of students and faculty—all key to solidifying our reputation among the world’s elite business schools. This year, you also helped set a new record for alumni support of Kellogg. Our applications and admissions numbers are up dramatically. We have outpaced our peer schools in career placements for new graduates. And we have broken ground on our new global hub. Your unwavering commitment to everything that Kellogg stands for helps make all that possible. Your continuing support keeps us on our trajectory to transform business education and practice to meet the challenges of the new economy. Thank you for investing in Kellogg today and securing the future for generations of courageous leaders to come. All the best, Sally Blount ’92, Dean 4 KELLOGG.NORTHWESTERN.EDU/INVEST contentS 6 Transforming Together 8 Early Investors 10 Kellogg Leadership Circle 13 Kellogg Investors Leaders Partners Innovators Activators Catalysts who gave $1,000 to $2,499 who gave up to $1,000 99 Corporate Affiliates 101 Kellogg Investors by Class Year 1929 1949 1962 1975 1988 2001 1934 1950 1963 1976 1989 2002
    [Show full text]